CYP1A2 rs2470103: Dietary Caffeine Metabolism and Inducibility
The rs2470103 variant is a single-nucleotide polymorphism located in an intronic region of the human CYP1A2 gene. Research links this variant to subtle differences in CYP1A2 enzyme expression and individual rates of dietary caffeine metabolism. Because evidence evaluating its standalone clinical impact remains limited, rs2470103 is primarily studied as a trait modifier rather than a diagnostic marker.
What each genotype means
Potential altered metabolic regulation
This genotype is located in the regulatory region of the CYP1A2 gene, which is responsible for the primary metabolism of caffeine. Research into this specific variant is limited, and while some studies suggest associations with caffeine-related metabolic responses, the functional impact remains less established than other well-studied markers like rs762551. Please discuss any concerns regarding caffeine sensitivity or medication metabolism with your clinician or pharmacist.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Potential altered metabolic regulation
This genotype is located in the regulatory region of the CYP1A2 gene, which is responsible for the primary metabolism of caffeine. Research into this specific variant is limited, and while some studies suggest associations with caffeine-related metabolic responses, the functional impact remains less established than other well-studied markers like rs762551. Please discuss any concerns regarding caffeine sensitivity or medication metabolism with your clinician or pharmacist.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Potential altered metabolic regulation
This genotype is located in the regulatory region of the CYP1A2 gene, which is responsible for the primary metabolism of caffeine. Research into this specific variant is limited, and while some studies suggest associations with caffeine-related metabolic responses, the functional impact remains less established than other well-studied markers like rs762551. Please discuss any concerns regarding caffeine sensitivity or medication metabolism with your clinician or pharmacist.
This genotype is common in many global populations, though exact frequencies vary significantly by ancestry.
Genetic Architecture and Variant Mapping
The single-nucleotide polymorphism rs2470103 is positioned on chromosome 15 within an intronic region of the cytochrome P450 family 1 subfamily A member 2 (CYP1A2) gene locus. As an intronic single-base transition involving cytosine (C) and thymine (T) alleles according to [dbSNP](https://www.ncbi.nlm.nih.gov/snp/rs2470103), this variant does not directly alter the amino acid sequence of the resulting enzyme. Instead, intronic polymorphisms in this genomic region can influence transcriptional regulation, splice-site recognition, or messenger RNA stability, thereby fine-tuning basal hepatic expression levels. It exists within an extensively studied linkage disequilibrium block on chromosome 15q24.1, often co-inherited with other prominent regulatory variants in the CYP1A cluster. Because non-coding variants can function as proxies for nearby regulatory motifs, cataloging the specific alleles of rs2470103 helps researchers track haplotypes that govern metabolic variation across human cohorts.
CYP1A2 Biological Function and Substrate Clearance
The CYP1A2 enzyme serves as a core component of the liver's phase I microsomal monooxygenase system, responsible for clearing numerous xenobiotics and endogenous molecules. As documented across biomedical resources like [MedlinePlus Genetics](https://medlineplus.gov/genetics/gene/cyp1a2/) and [PharmGKB](https://www.pharmgkb.org/gene/PA128), CYP1A2 is uniquely responsible for metabolizing upwards of ninety-five percent of dietary caffeine through hepatic N-3-demethylation into paraxanthine. In addition to handling methylxanthines, the enzyme facilitates the clearance of several therapeutic medications, including selected antipsychotics like clozapine and olanzapine, muscle relaxants such as tizanidine, and the bronchodilator theophylline. CYP1A2 is also notable for its wide inter-individual variability in baseline activity and its high inducibility; exposure to dietary cruciferous vegetables, charbroiled meats, and aromatic hydrocarbons from tobacco smoke can substantially upregulate transcription, altering clearance rates independent of baseline genetic code.
Scientific Evidence on Caffeine Metabolism and Trait Associations
Observational and genome-wide association studies surveyed in the [GWAS Catalog](https://www.ebi.ac.uk/gwas/search?query=rs2470103) associate rs2470103 and nearby regulatory markers with measurable variations in caffeine clearance and habitual beverage consumption patterns. Scientific literature indexed on [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=rs2470103) indicates that individuals carrying distinct intronic CYP1A2 alleles exhibit modest shifts in enzyme inducibility, with certain haplotypes conferring marginally faster or slower methylxanthine elimination. However, the scientific evidence specifically isolating rs2470103 remains categorized as limited. Much of its documented effect appears tied to broader haplotype structures, such as linkage with better-characterized variants like rs762551 (the defining marker of the CYP1A2*1F allele). Because external lifestyle factors—including cigarette smoking, oral contraceptive use, and dietary habits—frequently mask or amplify genetic differences, rs2470103 accounts for only a minor fraction of the overall phenotypic variance observed in population-wide caffeine response.
Translating Research to Daily Life
Discovering your rs2470103 genotype provides an interesting biological insight into how your liver handles caffeine, but it is not a diagnostic tool or a clinical prescription. Population studies associate slower clearance phenotypes with prolonged caffeine half-life and subjective sensitivity, such as evening sleep disruption or transient jitteriness following coffee intake. However, this statistical association cannot predict personal tolerance, nor does it establish an actionable threshold for dietary caffeine intake. Importantly, CYP1A2 is also involved in breaking down prescription medications, but you should never alter, pause, or self-adjust any medication dosage based on a direct-to-consumer genetic test. Any questions regarding drug dosing, polypharmacy, or pharmacogenomic testing must always be reviewed directly with a qualified physician or licensed clinical pharmacist.
How common is this variant?
The rs2470103 variant is widely distributed across global populations, with a minor allele frequency of approximately 0.35 reported across worldwide demographic registries.
Frequently asked questions
Does my rs2470103 genotype mean I should stop drinking coffee?
No, your rs2470103 genotype does not indicate that you need to avoid coffee or caffeine. This single-nucleotide variant is linked only to modest statistical shifts in caffeine breakdown rate across broad populations. Daily caffeine tolerance is shaped by multiple genetic loci alongside personal health status and lifestyle habits.
Can this genetic variant predict how I respond to prescription drugs?
While the CYP1A2 enzyme metabolizes several prescription medications, evidence linking rs2470103 by itself to drug toxicity or efficacy is limited. Established clinical guidelines primarily rely on comprehensively validated star-allele haplotypes rather than isolated intronic markers. Always consult your prescribing physician or a pharmacist before making any decisions about pharmaceutical treatments.
Why do non-genetic factors like smoking alter CYP1A2 activity?
The CYP1A2 gene contains responsive elements that bind to aryl hydrocarbon receptors, which are activated by compounds found in tobacco smoke and charbroiled foods. This environmental activation significantly upregulates enzyme production, often accelerating drug and caffeine clearance regardless of an individual's baseline genetic variant status.
How is rs2470103 related to other CYP1A2 caffeine variants like rs762551?
The rs2470103 variant sits on chromosome 15 in close physical proximity to other regulatory polymorphisms, including rs762551. Because these markers are frequently inherited together within common ancestral haplotypes, researchers often evaluate them jointly when investigating differences in hepatic enzyme inducibility.
Sources & further reading
Educational information only, last refreshed 9/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2470103?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP1A2
This variant in the CYP1A2 gene influences the hepatic metabolism rate of caffeine and is a key marker for individual differences in caffeine clearance.
Intronic marker associated with CYP1A2 enzyme activity and caffeine metabolism rates.
Modulates CYP1A2 inducibility affecting the rate of caffeine metabolism and clearance.
Regulatory variant associated with CYP1A2 enzyme activity, influencing the rate of caffeine metabolism and habitual coffee consumption.
A common variant in the CYP1A2 gene associated with caffeine metabolism rates.
Located in intron 1 of CYP1A2, this variant modulates inducible enzyme activity, altering systemic caffeine clearance and individual susceptibility to caffeine-related blood pressure increases.